COVID-19 vaccine Pfizer (3 doses) + COVID-19 vaccine Pfizer (2 doses) + COVID-19 mRNA Vaccine Moderna (3 doses) + COVID-19 mRNA Vaccine Moderna (2 doses) + COVID-19 mRNA Vaccine Moderna (1 dose)
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
84
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Covid19
Conditions
Covid19
Trial Timeline
Oct 5, 2021 โ Feb 28, 2023
NCT ID
NCT05047718About COVID-19 vaccine Pfizer (3 doses) + COVID-19 vaccine Pfizer (2 doses) + COVID-19 mRNA Vaccine Moderna (3 doses) + COVID-19 mRNA Vaccine Moderna (2 doses) + COVID-19 mRNA Vaccine Moderna (1 dose)
COVID-19 vaccine Pfizer (3 doses) + COVID-19 vaccine Pfizer (2 doses) + COVID-19 mRNA Vaccine Moderna (3 doses) + COVID-19 mRNA Vaccine Moderna (2 doses) + COVID-19 mRNA Vaccine Moderna (1 dose) is a approved stage product being developed by Sanofi for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT05047718. Target conditions include Covid19.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05047718 | Approved | Completed |
Competing Products
20 competing products in Covid19